Type 2 diabetes mellitus
Conditions
Interventions
Plateau group:None
Sponsors
The 940th Hospital of Joint Logistic Support Force
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Meeting the diagnostic criteria for T2DM as defined by the 2022 Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes . 2. Patients who have continuously taken dapagliflozin for more than 5 half-lives to reach steady-state plasma concentration. 3. Aged between 18 and 85 years, regardless of gender. 4. Patients provided informed consent for the study. 5. Concomitant use of other medications, or not, was permitted.
Exclusion criteria
Exclusion criteria: 1. Patients who have undergone major surgery within the past year. 2. Patients with severe cardiac, hepatic, or renal dysfunction. 3. Patients with severe hepatic or renal impairment. 4. Patients concurrently taking Rifampin and Mefenamic Acid, Sorafenib, or Donafenib. 5.Pregnant or lactating women 6.Patients with Type 1 Diabetes Mellitus or Diabetic Ketoacidosis. 7. Patients with malignant tumors. 8.Patients with psychiatric disorders or severe cognitive impairment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood drug concentration; | — |
Countries
China
Contacts
Public ContactRong Wang
The 940th Hospital of Joint Logistic Support Force
Outcome results
None listed